Salpeter S R
Primary Care Division, Santa Clara Valley Medical Center, San Jose, CA 95128.
West J Med. 1993 Nov;159(5):560-4.
Isoniazid chemoprophylaxis has long been known to be a highly effective means of preventing silent tuberculous infections from spreading to active disease. There has been much controversy, however, about the risk it carries for fatal hepatotoxicity. In this article I review the rate of fatal isoniazid-induced hepatitis during chemoprophylaxis that is done according to current monitoring guidelines. Information was obtained from a MEDLINE literature search and a survey of tuberculosis control officers in large metropolitan areas throughout the country. Data were included of patients who were monitored according to the American Thoracic Society's guidelines or who were treated after 1983 when the guidelines were published. The pooled results of the published studies showed no hepatotoxic deaths in 20,212 patients in whom prophylaxis was started. The unpublished data showed 2 deaths in 182,285 patients, for a combined rate of 0.001% (2 of 202,497). The death rate for those older than 35 years was estimated to be 0.002% (1 of 43,334). This rate is significantly lower than was previously estimated and should be used to reevaluate the benefit of preventive therapy for tuberculin-reactive patients older than 35. The risk of fatal isoniazid-induced hepatitis is negligible for all ages when patients are routinely monitored for liver toxicity.
长期以来,异烟肼化学预防一直被认为是预防潜伏性结核感染发展为活动性疾病的一种高效方法。然而,对于其引发致命肝毒性的风险存在诸多争议。在本文中,我回顾了按照当前监测指南进行化学预防期间,异烟肼诱发致命性肝炎的发生率。信息来源于医学文献数据库(MEDLINE)的文献检索以及对全国各大都市结核病防治官员的调查。纳入的数据包括按照美国胸科学会指南接受监测的患者,或者在1983年该指南发布后接受治疗的患者。已发表研究的汇总结果显示,在20212例开始接受预防治疗的患者中,无肝毒性死亡病例。未发表的数据显示,在182285例患者中有2例死亡,综合发生率为0.001%(202497例中的2例)。35岁以上人群的死亡率估计为0.002%(43334例中的1例)。这一发生率显著低于先前的估计值,应用于重新评估对35岁以上结核菌素反应阳性患者进行预防性治疗的益处。当对患者常规监测肝毒性时,异烟肼诱发致命性肝炎的风险在所有年龄段都可忽略不计。